MLSS vs SYK

For growth investors, Stryker Corporation (SYK) is the stronger pick with 11.

2% revenue growth year-over-year, versus -12. 2% for Milestone Scientific Inc. (MLSS). Stryker Corporation (SYK) offers the better valuation at 34. 0x trailing P/E (19. 1x forward), making it the more compelling value choice. Analysts rate Stryker Corporation (SYK) a "Buy" — based on 50 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Stryker Corporation (SYK) delivered a total return of +17.

5%, compared to -80. 6% for Milestone Scientific Inc. (MLSS). Over 10 years, the gap is even starker: SYK returned +179. 2% versus MLSS's -80. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Stryker Corporation (SYK) is the lower-risk stock at 0.

52β versus Milestone Scientific Inc. 's 0. 85β — meaning MLSS is approximately 62% more volatile than SYK relative to the S&P 500. On balance sheet safety, Milestone Scientific Inc. (MLSS) carries a lower debt/equity ratio of 6% versus 66% for Stryker Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Stryker Corporation (SYK) is pulling ahead at 11.

2% versus -12. 2% for Milestone Scientific Inc. (MLSS). On earnings-per-share growth, the picture is similar: Milestone Scientific Inc. grew EPS 37. 9% year-over-year, compared to 8. 2% for Stryker Corporation. Over a 3-year CAGR, SYK leads at 10. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Stryker Corporation (SYK) is the more profitable company, earning 12.

9% net margin versus -54. 6% for Milestone Scientific Inc. — meaning it keeps 12. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SYK leads at 19. 5% versus -78. 3% for MLSS. At the gross margin level — before operating expenses — MLSS leads at 74. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

In this comparison, SYK (1.

2% yield) pays a dividend. MLSS does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Stryker Corporation (SYK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

52), 1. 2% yield, +179. 2% 10Y return). Both have compounded well over 10 years (SYK: +179. 2%, MLSS: -80. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

SYK pays a dividend while MLSS does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.